The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis via Differential Cellular Pathways
Xinwei Cao,1 Yajun Li,1 Jianrong Shi,2 Huifang Tang1 1Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of China; 2Department of Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine,...
Guardado en:
Autores principales: | Cao X, Li Y, Shi J, Tang H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ad5d3c3a9d8740859ab52884a897f59a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Arecoline Enhances Phosphodiesterase 4A Activity to Promote Transforming Growth Factor-β-Induced Buccal Mucosal Fibroblast Activation via cAMP-Epac1 Signaling Pathway
por: Bo Zhang, et al.
Publicado: (2021) -
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
por: Michalski JE, et al.
Publicado: (2021) -
Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis—a systematic review protocol
por: Revati Amin, et al.
Publicado: (2021) -
Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
por: Henrik Jessen, et al.
Publicado: (2021) -
The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Wan-Tong Zhang, et al.
Publicado: (2021)